Satralizumab
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 187 publications
Satralizumab could reduce relapse risk in people with MOGAD.
Journal: Nature reviews. Neurology
Published: May 06, 2026
How are interleukin-6 receptor antagonists shaping the future of neuromyelitis optica spectrum disorder?
Journal: Expert review of neurotherapeutics
Published: May 02, 2026
Updates on the Acute and Maintenance Management of Optic Neuritis Including Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody Disease.
Journal: Neurologic clinics
Published: April 01, 2026
Unmet needs in the care of patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody associated disease: insights from Germany.
Journal: Neurological research and practice
Published: March 24, 2026
Intitiation of satralizumab during pregnancy for successful childbirth in neuromyelitis optica spectrum disorder: A case report and literature review.
Journal: Journal of neuroimmunology
Published: March 21, 2026
Satralizumab in the management of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder during pregnancy: a case report.
Journal: Frontiers in immunology
Published: March 18, 2026
Monoclonal antibody efficacy in seropositive vs seronegative NMOSD: systematic review and meta-analysis.
Journal: Journal of neuroimmunology
Published: March 15, 2026
Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: February 24, 2026
Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics.
Journal: Internal medicine (Tokyo, Japan)
Published: February 23, 2026
Diverticular Perforation with Normal C-reactive Protein in a Patient with Neuromyelitis Optica Spectrum Disorder Receiving Satralizumab.
Journal: Internal medicine (Tokyo, Japan)
Published: February 11, 2026
Genotype-guided switch from ravulizumab to satralizumab in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder: a case of C5 polymorphism-associated ravulizumab resistance.
Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: January 21, 2026
Last Updated: 06/30/2026